RETROSPECTIVE ANALYSIS OF THE RESULTS OF SYSTEMIC THERAPY OF MODERATE TO SEVERE PAPULO-PUSTULAR ACNE

Q4 Medicine
Irina Khismatulina, Еlena Faizullina
{"title":"RETROSPECTIVE ANALYSIS OF THE RESULTS OF SYSTEMIC THERAPY OF MODERATE TO SEVERE PAPULO-PUSTULAR ACNE","authors":"Irina Khismatulina, Еlena Faizullina","doi":"10.25208/vdv5711","DOIUrl":null,"url":null,"abstract":"Background: Systemic isotretinoin is an effective treatment for acne, but the significant relapse rate requires a search for optimal daily doses to prolong disease remission.
 Purpose: To compare the results of systemic therapy of moderate-to-severe resistant and severe papulopustular pustular acne with isotretinoin at daily doses of 0.5; 0.7 and 1.0 mg/kg body weight.
 Methods: In a retrospective study, data from outpatient records and facial skin corneometry results of 125 individuals (95 acne patients, 30 healthy individuals) were analyzed. Patients with acne received isotretinoin (Sotret)at a daily dose of0.5; 0.7 or 1.0 mg/kg body weight, with a cumulative dose of 120 mg/kg body weight in all patients. The duration of follow-up of patients, according to outpatient records, was 18 months.
 Results: Isotretinoin systemic therapy was effective in patients in all compared groups. The resolution of inflammatory elements was faster (p0.001) in those who received doses of isotretinoin 0.7 and 1.0 mg/kg body weight. After treatment, elevated values of sebumetry, skin relief, pore size, and pigmentation were normalized in all groups. There was a significant difference in the incidence of adverse events depending on the dose of isotretinoin. The number of patients with relapses registered at 18-week follow-up after therapy in Group I was 6 (18.75%); in Group II, 4 (12.5%); in Group III, 1 (3.2%), the differences between the groups being significant (p=0.003).
 Conclusion: Therapy of moderate-to-severe resistant and severe papulopustular acne with systemic isotretinoin (Sotret) at daily doses of 0.5; 0.7 and 1.0 mg/kg at a cumulative dose of 120 mg/kg body weight demonstrates comparable clinical efficacy. However, recurrence rates during the 18-month follow-up period correlated with the daily dose of the drug.","PeriodicalId":23618,"journal":{"name":"Vestnik dermatologii i venerologii","volume":"216 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vestnik dermatologii i venerologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25208/vdv5711","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Systemic isotretinoin is an effective treatment for acne, but the significant relapse rate requires a search for optimal daily doses to prolong disease remission. Purpose: To compare the results of systemic therapy of moderate-to-severe resistant and severe papulopustular pustular acne with isotretinoin at daily doses of 0.5; 0.7 and 1.0 mg/kg body weight. Methods: In a retrospective study, data from outpatient records and facial skin corneometry results of 125 individuals (95 acne patients, 30 healthy individuals) were analyzed. Patients with acne received isotretinoin (Sotret)at a daily dose of0.5; 0.7 or 1.0 mg/kg body weight, with a cumulative dose of 120 mg/kg body weight in all patients. The duration of follow-up of patients, according to outpatient records, was 18 months. Results: Isotretinoin systemic therapy was effective in patients in all compared groups. The resolution of inflammatory elements was faster (p0.001) in those who received doses of isotretinoin 0.7 and 1.0 mg/kg body weight. After treatment, elevated values of sebumetry, skin relief, pore size, and pigmentation were normalized in all groups. There was a significant difference in the incidence of adverse events depending on the dose of isotretinoin. The number of patients with relapses registered at 18-week follow-up after therapy in Group I was 6 (18.75%); in Group II, 4 (12.5%); in Group III, 1 (3.2%), the differences between the groups being significant (p=0.003). Conclusion: Therapy of moderate-to-severe resistant and severe papulopustular acne with systemic isotretinoin (Sotret) at daily doses of 0.5; 0.7 and 1.0 mg/kg at a cumulative dose of 120 mg/kg body weight demonstrates comparable clinical efficacy. However, recurrence rates during the 18-month follow-up period correlated with the daily dose of the drug.
中重度丘疹性脓疱性痤疮全身治疗的回顾性分析
背景:全身异维a酸是治疗痤疮的有效方法,但复发率高,需要寻找最佳的每日剂量以延长疾病缓解期。目的:比较异维甲酸每日剂量0.5对中重度耐药和重度丘疹性脓疱性痤疮的全身治疗效果;0.7和1.0 mg/kg体重。 方法:回顾性分析125例患者(痤疮患者95例,健康者30例)的门诊记录和面部皮肤角膜测量结果。痤疮患者接受异维甲酸(Sotret),每日剂量为0.5;0.7或1.0 mg/kg体重,所有患者累积剂量为120 mg/kg体重。根据门诊记录,患者随访时间为18个月。 结果:各组患者异维甲酸全身治疗均有效。在接受异维甲酸0.7和1.0 mg/kg体重组中,炎症因子的消退速度更快(p0.001)。治疗后,各组皮脂测量、皮肤缓解、毛孔大小和色素沉着的升高值均归一化。根据异维甲酸的剂量不同,不良事件的发生率有显著差异。第一组治疗后随访18周复发患者6例(18.75%);第二组4例(12.5%);ⅲ组1(3.2%),组间差异显著(p=0.003)。 结论:系统异维a酸(Sotret)每日0.5剂量治疗中重度耐药和重度丘疹性痤疮;0.7和1.0 mg/kg,累积剂量为120 mg/kg体重,显示出相当的临床疗效。然而,在18个月的随访期间,复发率与药物的日剂量相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
40
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信